Abstract LB289: Longitudinal ctDNA levels and clinical outcomes of first-line (1L) tislelizumab (TIS) + chemotherapy (chemo) treatment for advanced non-small cell lung cancer (NSCLC) in the RATIONALE-304 and 307 studies
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb289
Abstract: Background: The role of circulating tumor DNA (ctDNA) in monitoring response to immunotherapy in NSCLC is unconfirmed. This is a retrospective analysis of association between longitudinal ctDNA levels and clinical outcomes in 1L TIS (anti-PD-1)… read more here.
Keywords: ctdna; pfs; rationale 304; ctdna levels ... See more keywords